At the news
? NEUTRALIMPACT 4/10 6-K filed Nov 10, 2026 at 07:01 ET
BioNTech announced it will acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The PRV will be used to support a future regulatory filing for a late-stage oncology asset, potentially accelerating approval timelines.
- BioNTech agreed to acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
- The PRV reduces the FDA review timeline for a single application and could lead to expedited approval.
- BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline.
- The transaction is subject to customary closing conditions, including HSR antitrust clearance.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access